Медицинские вопросы и проблемы подростков, больных муковисцидозом

174

Hayes E, Pohl K, McElvaney NG, Reeves EF1 The cystic fibrosis neutrophil: a specialized yet potentially defective cell. Arch Immunol Ther Exp 2011; 59:97-112

175

Hartl D, Latzin P Hordijk P et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007; 13:1423-30

176

Griese M, Kappler M, Gaggar A, Hartl D. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J 2008;32:783-95

177

Hilliard TN, Regamey N, Shute JK et al. Airway remodelling in children with cystic fibrosis. Thorax 2007; 62:1074-80

178

Regamey N, Ochs M, Hilliard TN et al. Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2008; 177:837-13

179

Laguna ТА, Wagner BD, Starcher В et al. Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation. Pediatr Pulmonol 2012;47:856-63

180

Regamey N, Tsartsali L, Hilliard TN et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax 2012; 67:164-70

181

Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 2011; 184:252-8

182

Xiao H, Li DX, Liu M. Knowledge translation: airway epithelial cell migration and respiratory diseases. Cell Mol Life Sci 2012. (In press) DOI: 10.1007/s00018-012-1044-z

183

Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 2010;298:L715-31

184

Rock JR, Hogan BL. Epithelial progenitor cells in lung development, maintenance, repair, and disease. Annu Rev Cell Dev Biol 2011; 27:493-512

185

Hegab AE, Ha VL, Gilbert JL et al. Novel stem/progenitor cell population from murine tracheal submucosal gland ducts with multipotent regenerative potential. Stem Cells 2011; 29:1283-93

186

Hong KU, Reynolds SD, Giangreco A, Hurley CM, Stripp BR. Clara cell secretory protein-expressing cells of the airway neuroepithelial body microenvironment include a label-retaining subset and are critical for epithelial renewal after progenitor cell depletion. Am J Respir Cell Mol Biol 2001; 24:671-81

187

Fujino N, Kubo H, Suzuki T et al. Isolation of alveolar epithelial type II progenitor cells from adult human lungs. Lab Invest 2011; 91:363-78

188

Krause DS. Bone marrow-derived lung epithelial cells. Proc Am Thorac Soc 2008; 5:699-702

189

Legrand C, Gilles C, Zahm JM et al. Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling. J Cell Biol 1999;146:517-29

190

Legrand C, Polette M, Tournier JM et al. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res 2001; 264:326-36

191

Xiao H, Li DX, Liu M. Knowledge translation: airway epithelial cell migration and respiratory diseases. Cell Mol Life Sci 2012. (In press) DOI: 10.1007/s00018-012-1044-z

192

Hajj R, Lesimple P Nawrocki-Raby B, Birembaut P Puchelle E, Coraux С Human airway surface epithelial regeneration is delayed and abnormal in cystic fibrosis. J Pathol 2007;211:340-50

193

Trinh NT, Prive A, Maille E, Noel J, Brochiero E. EGF and K+ channel activity control normal and cystic fibrosis bronchial epithelia repair. Am J Physiol Lung Cell Mol Physiol 2008; 295:L866-80

194

Trinh NT Bardou O, Prive A et al. Improvement of defective cystic fibrosis airway epithelial wound repair after CFTR rescue. Eur Respir J 2012. (In press) DOI: 10.1183/09031936.00221711

195

Saiman L, Prince A. Pseudomonas aeruginosa pili bind to asialo GM1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest 1993;92:1875-80

196

Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997; 145:794-803

197

Davis PB. The gender gap in cystic fibrosis survival. J Gend Specif Med 1999;2:47-51

198

Verma N, Bush A, Buchdahl R. Is there still a gender gap in cystic fibrosis? Chest 2005; 128:2824-34

199

Moran A, Becker D, Casella SJ et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010; 33:2677-83

200

Brennan AL, Gyi KM, Wood DM et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros 2007; 6:101-9

201

Walters S. Sex differences in weight perception and nutritional behaviour in adults with cystic fibrosis. J Hum Nutr Diet 2001; 14:83-91

202

Towns SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75

203

Cystic Fibrosis Foundation Patient Registry: 2003 Annual Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation, 2004

204

Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999; 30:1151-8

205

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

206

Wilschanski M, Durie PR. Patterns of Gl disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56:1153-63

207

Wilschanski M, Durie PR. Patterns of Gl disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56:1153-63

208

Durieu I, Pellet O, Simonot L et al. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol 1999;30:1052-6

209

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

210

Wilschanski M, Durie PR. Patterns of Gl disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56:1153-63

211

Lewindon PJ, Pereira TN, Hoskins AC et al. The role of hepatic stellate cells and transforming growth factor-|31 in cystic fibrosis liver disease. Am J Pathol 2002; 160:1705-15

212

Linblad A, Hultcrantz R, Strandvik B. Bile-duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology 1992; 16:372-81

213

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

214

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

215

Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999; 30:1151-8

216

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

217

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

218

Lewindon PJ, Shepherd RW, Walsh M et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53:193-201

219

Mueller-Abt PR, Frawley KJ, Greer RM, Lewindon PJ. Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease. J Cyst Fibros 2008; 7:215-21

220

Lewindon PJ, Shepherd RW, Walsh M et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53:193-201

221

Lewindon PJ, Shepherd RW, Walsh M et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53:193-201

222

Lewindon PJ, Shepherd RW, Walsh M et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53:193-201

223

Gilmore IT Burroughs A, Murray-LyonlM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995;36:437-41

224

Ooi CY, Nightingale S, Durie P Freedman SD. Ursodeoxycholic acid in cystic fibrosis-associated liver disease. J Cyst Fibros 2012; 11:72-3

225

O'Brien SM, Campbell GR, Burke AF et al. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. Eur J Gastroenterol Hepatol 1996; 8:477-83

226

Van de Meeberg PC, Houwen RH, Sinaasappel M et al. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol 1997;32:369-73

227

Colombo C, Castellani MR, Balistreri WF et al. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992; 15:677-84

228

Bartlett JR, Friedman KJ, Ling SC et al. Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302:1076-83

229

Lewindon PJ, Shepherd RW, Walsh M et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53:193-201

230

Hui CK, Belaye T, Montegrande К et al. Acomparison in the progression of liver fibrosis in chronic hepatitis С between persistently normal and elevated transaminase. J Hepatol 2003;38:511-17

231

Kumar M, Sarin SK, Hissar S et al. Virologic and histologic features of chronic hepatitis В virus-infected asymptomatic patients with persistently normal ALT Gastroenterology 2008; 134:1376-84

232

Lindblad A, Glaumann H, Strandvik B. Atwo-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998;27:166-74

233

Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2000; (2):CD00222

234

Lindblad A, Glaumann H, Strandvik B. Atwo-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998;27:166-74

235

Siano M, De Gregorio F, Boggia В et al. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease. Dig Liver Dis 2010; 42:428-31

236

Lindor KD, Kowdley KV, Luketic VA et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14

237

Gong Y, Huang ZB, Christensen E, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2008; (3):CD000551

238

Lindor KD, Kowdley KV, Luketic VA et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14

239

Colombo C, Bertolini E, Assaisso ML et al. Failure of ursodeoxycholic acid to dissolve radiolucent gallstone in patients with cystic fibrosis. Acta Paediatr 1993;82:562-5

240

Gana JC, Turner D, Mieli-Vergani G et al. A clinical prediction rule and platelet count predict esophageal varices in children. Gastroenterology 2011;141:2009-16

241

Pozler O, Krajina A, Vanicek H et al. Transjugular intrahepatic portosystemic shunt in five children with cystic fibrosis: long-term results. Hepatogastroenterology 2003;50:1111-14

242

Lillegard JB, Hanna AM, McKenzie TJ, Moir CR, Ishitani MB, Nagorney DM. A single-institution review of portosystemic shunts in children: an ongoing discussion. HPB Surg 2010; 2010:964597

243

Linnane B, Oliver MR, Robinson PJ. Does splenectomy in cystic fibrosis related liver disease improve lung function and nutritional status? A case series. Arch Dis Child 2006; 91:771-3

244

Aslanidou E, Fotoulaki M, Tsitouridis I, Nousia-Arvanitakis S. Partial splenic embolization: successful treatment of hypersplenism, secondary to biliary cirrhosis and portal hypertension in cystic fibrosis. J Cyst Fibros 2007; 6:212-14

245

Lamireau T, Martin S, Lallier M et al. Liver transplantation for cirrhosis in cystic fibrosis. Can J Gastroenterol 2006; 20:475-8

246

Melzi ML, Kelly DA, Colombo С et al. Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transpl Int 2006; 19:726-31

247

Mendizabal M, Reddy KR, Cassuto J etal. Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data. Liver Transpl 2011; 17:243-50

248

Barshes NR, DiBardino DJ, McKenzie ED et al. Combined lung and liver transplantation: the United States experience. Transplantation 2005; 80:1161-7

249

Mekeel KL, Langham MR Jr, Gonzalez-Peralta R et al. Combined en bloc liver pancreas transplantation for children with CF. Liver Transpl 2007; 13:406-9

250

Noble-Jamieson G, Barnes N, Jamieson N et al. Liver transplantation for hepatic cirrhosis in cystic fibrosis. J R Soc Med 1996; 89(Suppl 27):31-7

251

Noble-Jamieson G, Barnes N, Jamieson N et al. Liver transplantation for hepatic cirrhosis in cystic fibrosis. J R Soc Med 1996; 89 (Suppl 27): 31-7

252

Melzi ML, Kelly DA, Colombo С et al. Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transpl Int 2006; 19:726-31

253

Accurso FJ, Rowe SM, Clancy JP et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363:1991-2003

254

Ramsey В, Dong Q, Yen К, Elborn J. Efficacy and safety of VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation. Pediatr Pulmonol 2011; 46(S34):286-7

255

Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: Challenges to disease self-management. J Cyst Fibros 2009; 8:91-6

256

Ernst MM, Johnson MC, Stark LJ. Developmental and psychosocial issues in cystic fibrosis. Pediatr Clin North Am 2011;58:865-85

257

Modi AC, Marciel KK, Slater SK, Drotar D, Quittner AL. The influence of parental supervision on medical adherence in adolescents with cystic fibrosis: developmental shifts from pre to late adolescence. Child Health Care 2008; 37:78-92

258

Kettler LJ, Sawyer SM, Winefield HR, Greville HW. Determinants of adherence in adults with cystic fibrosis. Thorax 2002;57:459-64

259

Quittner AL, Espelage DL, levers-Landis C, Drotar D. Measuring adherence to medical treatments in childhood chronic illness: considering multiple methods and sources of information. J Clin Psychol Med Settings 2000; 7:41-54

260

Rapoff M. Adherence to pediatric medical regimens. 2nd edition. New York: Springer, 2010: 232

261

Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol 2001; 54 (12 Suppl 1):S57-S60

262

La Greca AM, Bearman KJ. Adherence to prescribed medical regimens. In: Roberts MC, ed. Handbook of pediatric psychology. 3rd edition. New York: Guilford, 2003:119-10

263

Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol 2006;31:846-58

264

Quittner AL, Drotar D, levers-Landis C, Slocum N, Seidner D, Jacobsen J. Adherence to medical treatments in adolescents with cystic fibrosis: the development and evaluation of family-based interventions. In: Drotar D, ed. Promoting adherence to medical treatment in chronic childhood illness: concepts, methods, and interventions. Mahwah, USA: Lawrence Erlbaum Associates, 2000: 383-407

265

Burrows JA, Bunting JP, Masel PJ, Bell SC. Nebulised dornase alpha: adherence in adults with cystic fibrosis. J Cyst Fibros 2002; 1:255-9

266

Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011; 140:425-32

267

Eakin MN, Bilderback A, Boyle MR Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011; 10:258-64

268

McNamara PS, McCormack P McDonald AJ, Heaf L, Southern KW. Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J Cyst Fibros 2009; 8:258-63

269

Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multimethod assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006; 5:177-85

270

Rapoff M. Adherence to pediatric medical regimens. 2nd edition. New York: Springer, 2010: 232

271

Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol 2001; 54 (12 Suppl 1):S57-S60

272

Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol 2006;31:846-58

273

Abbott J, Dodd M, Gee L, Webb K. Ways of coping with cystic fibrosis: implications for treatment adherence. Disabil Rehabil 2001; 23:315-24

274

Zindani GN, Streetman DD, Streetman DS, Nasr SZ. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health 2006; 38:13-7

275

Smith BA, Modi AC, Quittner AL, Wood BL. Depressive symptoms in children with cystic fibrosis and parents and its effects on adherence to airway clearance. Pediatr Pulmonol 2010;45:756-63

276

Quittner AL, Slater S. Parenting stress, depression, and caregiving for young children with cystic fibrosis. Pediatr Pulmonol Suppl 2005;40:180-1

277

White T, Miller J, Smith GL, McMahon WM. Adherence and psychopathology in children and adolescents with cystic fibrosis. Eur Child Adolesc Psychiatry 2009; 18:96-104

278

DeLambo KE, levers-Landis CE, Drotar D, Quittner AL. Association of observed family relationship quality and problem-solving skills with treatment adherence in older children and adolescents with cystic fibrosis. J Pediatr Psychol 2004; 29:343-53

279

DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 2004;23:207-18

280

Ernst MM, Johnson MC, Stark LJ. Developmental and psychosocial issues in cystic fibrosis. Pediatr Clin North Am 2011;58:865-85

281

Modi AC, Lim CS, Driscoll KA, Piazza-Waggoner C, Quittner AL, Wooldridge J. Changes in pediatric health-related quality of life in cystic fibrosis after IV antibiotic treatment for pulmonary exacerbations. J Clin Psychol Med Settings 2010;17:49-55

282

Sawicki GS, Rasouliyan L, McMullen AH et al. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol 2011;46:36-44

283

Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmershevlin N. Medication compliance – a health-care problem. Ann Pharmacother 1993; 27 (9 Suppl):S1-24

284

Balkrishnan R. The importance of medication adherence in improving chronic-disease related outcomes – what we know and what we need to further know. Med Care 2005; 43:517-20

285

Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmershevlin N. Medication compliance – a health-care problem. Ann Pharmacother 1993; 27 (9 Suppl):S1-24

286

Osterberg L, Blaschke T Adherence to medication. New Engl J Med 2005; 353:487-97

287

Sabate E, ed. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003. Available at: http://www.who. int/chp/knowledge/publications/adherence_report/en/ Last accessed October 2012.

288

DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42:200-9

289

Briesacher BA, Quittner AL, Fouayzi H, Zhang J, Swensen A. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007 Pediatr Pulmonol 2011;46:770-6

290

Osterberg L, Blaschke T Adherence to medication. New Engl J Med 2005; 353:487-97

291

Quittner AL, Modi AC, Lemanek KL, levers-Landis CE, Rapoff MA. Evidence-based assessment of adherence to medical treatments in pediatric psychology. J Pediatr Psychol 2008; 33:916-36

292

Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multimethod assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006; 5:177-85

293

Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011; 140:425-32